BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 20
• 22
• 23
• 24
• 25
• 26
• 27
• 30
• 31

• Press Releases

  Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

  March 3, 2026

   · 

  3 min read
• Press Releases

  Kyverna Therapeutics to Participate in Upcoming March 2026 Investor Conferences

  March 3, 2026

   · 

  1 min read
• Press Releases

  Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference

  March 3, 2026

   · 

  1 min read
• Press Releases

  TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company’s Dedication to Improving the Lives of Cancer Patients

  March 3, 2026

   · 

  6 min read
• Press Releases

  Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

  March 3, 2026

   · 

  10 min read
• Press Releases

  Acumen Pharmaceuticals to Showcase Advances in Alzheimer’s Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026

  March 3, 2026

   · 

  7 min read
• Press Releases

  BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT)

  March 3, 2026

   · 

  6 min read
• Press Releases

  COUR Pharma Announces Positive One-Year Results from the Phase 2a Study of CNP-104 in Primary Biliary Cholangitis

  March 3, 2026

   · 

  4 min read
• Press Releases

  Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share

  March 3, 2026

   · 

  4 min read
• Press Releases

  Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference

  March 3, 2026

   · 

  4 min read